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Abstract
Objective: Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the
treatment aims to achieve results with the least possible treatment-related morbidity. The aim of
this study was to assess the outcomes of pediatric patients withMOGCT.
Methods: Patients were treated according to their stage: surgery and surveillance for stage I;
a modified bleomycin–etoposide–cisplatin (BEP) regimen for stages II (three cycles), III, and IV
(three cycles) with surgery on residual disease.
Results: Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma
(Dysg), 13with immature teratomaandelevated serumalpha-fetoprotein levels (IT+AFP), and38
with nondysgeminoma (Non-Dysg) staged as follows: 27 stage I, 13 stage II, 32 stage III, 5 stage IV.
Among evaluable patients in stage I (5-year event-free survival [EFS] 72.1% [95%CI: 56.4–92.1%];
5-year overall survival [OS] 100%), seven relapsed (three patients with Dysg and four patients
with Non-Dysg) andwere rescuedwith chemotherapy (plus surgery in three patients). Among the
evaluable patients with stages II–IV, 48 (98%) achieved complete remission after chemotherapy
± surgery, one (IT + AFP, stage IV) had progressive disease. In the whole series (median follow-up
80 months), the 5-year OS and EFS were 98.5% (95% CI: 95.6–100%) and 84.5% (95% CI: 76.5–
93.5%).
Conclusions:We confirm the excellent outcome for MOGCT. Robust data are lacking on surgical
staging, surveillance for Non-Dysg with stage I, themanagement of IT+AFP, and themost appro-
priate BEP regimen. As pediatric oncologists, we support the role of surveillance after proper sur-
gical staging providing cases aremanaged by experts at specialized pediatric centers.
K EYWORDS
childhood, germ cell tumors, ovarian
Abbreviations: AFP, serum alpha-fetoprotein; BEP, bleomycin–etoposide–cisplatin;
betaHCG, beta-human chorionic gonadotropin; CR, complete remission; Dysg,
dysgerminoma; EFS, event-free survival; GCT, germ cell tumors; IT, immature teratoma; LNS,
lymph node sampling; MOGCT, malignant ovarian germ cell tumors; Non-Dysg,
nondysgerminoma; OO, oophorectomy; OS, overall survival; PD, progressive disease; PR,
partial remission; PWC, peritoneal washing cytology; YST, yolk sac tumor
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1 INTRODUCTION
Malignant ovarian germ cell tumors (MOGCT) are rare, accounting
for 2–3% of all ovarian malignancies. They usually develop in children
and adolescents, or young women1 with a median age at diagnosis of
16 years (range 6–60 years). Patients are treated at pediatric depart-
ments as well as gynecology units. An initial surgery may also some-
times be managed at nonspecialized centers, and inadequate surgical
staging is common.2 Luckily, the survival rates for children with malig-
nant germ cell tumors (GCT) generally have greatly improved.
Based on a previous national experience,3 a new study onmalignant
non-CNS GCT launched by the Associazione Italiana Ematologia Oncolo-
gia Pediatrica (the “TCGM-AIEOP-2004study”) aimed toextend theage
of enrolment from ≤16 to <18 years, to avoid further treatment after
surgery for all localized (stage I)MOGCT, and to adopt standard combi-
nation chemotherapy (bleomycin–etoposide–cisplatin, BEP) with dose
adjustments to limit late effects. The present study examines the out-
comes.
2 METHODS
Patients with MOGCT were registered for the second national
prospective protocol as part of theTCGM-AIEOP-2004 study. Thepro-
tocol was approved by the local ethical committees.
Patients under 18 years of age with histologically proven MOGCT
(dysgerminoma [Dysg] or nondysgerminoma [Non-Dysg], i.e., yolk sac
tumor [YST], embryonal carcinoma; choriocarcinoma, immature ter-
atoma [IT] with elevated serum alpha-fetoprotein [AFP] levels for age,
without any cutoff, or mixed forms with two or more components)
were enrolled. Patients with no tumor histology at diagnosis, but with
highAFP and/or beta-human chorionic gonadotropin (betaHCG) levels
could also be included. AFP and betaHCG were assayed at diagnosis,
before each cycle of chemotherapy, or until normalization after com-
pleting the treatment(s). Patients were followed up with abdominal
ultrasound, chest X-rays, and AFP and betaHCG assay every 2 months
in the first year after completing any treatment, every 3 months in the
second year, then 6-monthly until the fifth year. After the fifth year,
follow-up was at the discretion of the local center. Staging was done
with themodifiedChildren’sOncologyGroup system4–8 (Table 1). Cen-
tralized pathology reviewwas encouraged, but not mandatory.
2.1 Treatment
Patients underwent initial surgery (biopsy or oophorectomy [OO]).
Initial OO was recommended when complete resection was judged
feasible. The procedure included complete resection of the ovary
involved (without violating the tumor capsule), sparing the unaffected
fallopian tube, peritoneal washing cytology (PWC), visual inspection
of the opposite ovary with biopsy of suspected nodules, infracolic
omentectomy, biopsy of any suspect areas, and lymph node sam-
pling (LNS). After February 2013, the approach wasmodified, omitting
omentectomy and LNS, with palpation of the retroperitoneal lymph
node, and biopsy if abnormally enlarged. Biopsy was recommended if
complete resection was unfeasible, and OOwas mandatory at the end
of chemotherapy.
Treatments depended on stage: patients with stage I, any histology,
and tumor markers returning to normal after surgery, remained under
surveillance without any chemotherapy. The others received a mod-
ified BEP regimen (cisplatin 25 mg/m2 daily on days 1–4; etoposide
100 mg/m2 daily on days 1–4; bleomycin 15 mg/m2 on day 2, once per
cycle), every 21 days (three cycles for stage II, four for stages III and IV,
or persistently highmarkers after surgery). After chemotherapy, resec-
tion of radiologically evident residual disease was suggested. Bilat-
eral disease wasmanaged surgically, sparing the less-involved ovary to
avoid castration.
2.2 Response criteria
Patients with normal tumor markers and no imaging abnormalities
were classified as complete remissions (CR). Patients with negative
imaging and lower tumormarkers, orwith imaging abnormalities at the
primary tumor/regional sites and declining/normalizing tumor mark-
ers, were classed as partial remissions (PRs). Patients with amore than
25% increase in tumor size, new lesions, and/or rising tumor markers
were classified as progressive disease (PD). Patientswith PR and resid-
ual tumor underwent surgical exploration, and postoperative assess-
ments depended on histological findings, classified as fibronecrotic tis-
sue residual teratoma and viable malignant cells.4
2.3 Statistical analysis
Overall survival (OS) was defined as the time elapsing from diagno-
sis to death from any cause. Time was censored as at the last follow-
up for patients still alive. Event-free survival (EFS) was defined as the
time from diagnosis to any event (malignant germ cell recurrence,
teratoma, teratoma with malignant transformation, death, whichever
occurred first). Time was censored as at the last follow-up for patients
still alive and event-free. The OS and EFS curves were estimated using
the Kaplan–Meier method,9 and compared using the log-rank test.
All patients were included in the OS and EFS analyses regardless of
whether they complied with the treatment program. EFS was cen-
sored at 1 month for two patients (the time elapsing from diagnosis
to last follow-up), but their survival status could be retrieved from the
records, and they could contribute to theOS curves as censored obser-
vations for a longer interval. Themedian follow-upwas estimatedwith
the reverse Kaplan–Meier method, using theOS data.10
3 RESULTS
FromMarch 2004 to December 2015, 77 patients were accrued from
17 institutions, with a median age of 11.8 years (range 1.8–17.2), and
a median follow-up of 80 months (range 14–149). Four females had
chromosomal abnormalities (Turner syndrome in two, Proteus syn-
drome in one, a constitutional 8–22 translocation in one) and three
had relativeswith tumors (a sister with ovarian teratoma, a father with
seminoma, a brother with low-grade glioma). Patients were staged as
follows: 27 stage I (35%), 13 stage II (17%), 32 stage III (42%), and
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TABLE 1 Staging of malignant ovarian germ cell tumors (modified according to the Children’s Oncology Group)
Stage Description
I Limited to ovary, peritoneal washing negative for malignant cells; no clinical, radiological, or histological evidence of disease beyond
the ovaries (gliomatosis peritonei did not result in upstaging); tumormarkers negative after appropriate half-life decline
II Microscopic residual or positive lymph nodes (<2 cm); peritoneal washing negative for malignant cells (gliomatosis peritonei did not
result in upstaging); tumormarkers positive or negative
III Gross residual or biopsy only, tumor-positive lymph node(s)>2 cm in diameter; contiguous visceral involvement (omentum, intestine,
bladder); peritoneal washing positive for malignant cells; tumormarkers positive or negative
IV Distant metastases, whichmay include liver and/or persistent elevation of tumormarkersa
aModified from original Children’s Oncology Group Staging System.
5 stage IV (6%). The histotype distribution was as follows: 26 Dysg
(34%), and 38Non-Dysg (49%), and 13 (17%) IT (Grade 2 in six, Grade 3
in seven)withelevatedAFP levels (median140ng/ml, range50–3,863).
Central pathology review was performed for 38 of 77 (49%) cases and
all but two diagnoses were confirmed (Table 2) .
Dysg: Among 26 patients, 13 were stage I. One patient was lost
to follow-up after 1 month of observation; all the others were moni-
tored closely after surgery. Five patients had surgery according to the
original guidelines, five according to the revised version, two under-
went OO, and one unknown. Three patients (one without PWC, two
properly staged) relapsed 21, 25, and 40 months after their diagnosis
(Table 3); all three are alive in CR, after chemotherapy in two cases, and
after chemotherapy plus subsequent surgery with no impact on fertil-
ity in one. The six stage II cases underwent surgery and three cycles of
BEP chemotherapy, all achieving CR. The reason for staging them as II
were as follows: metastatic lymph nodes in two, malignant cells in per-
itubaric tissue in two, and tumor rupture in two.
The reason for seven cases being stage III were metastatic lymph
nodes in three, PWC positive in two, and residual disease in two.
Six patients received four cycles of chemotherapy, achieving CR. One
achieved PR after biopsy and BEP, then underwent delayed surgery
revealing viable malignant cells. For all Dysg patients, the 5-year OS
was 100%, and the 5-year EFSwas 86.6%overall (95%CI: 73.4–100%),
and 72.9% (95%CI: 50.7–100%) and 100% for stage I and stages II and
III, respectively.
IT± AFP: Three females with stage I (AFP: 65, 97, 3,863) weremon-
itored closely after surgery and no chemotherapy. One had surgery
according to the original guidelines, two according to the revised ver-
sion; none relapsed.One patientwith stage II (AFP 178) had peritoneal
implants totally removed and chemotherapy; she was alive in CR.
The reason for eight cases (AFP: 50–1,438) being classified as stage
III were as follows: peritoneal implants and/or residual mass in five,
PWCpositivity in two, unknown in one. One patient was lost to follow-
up after one cycle of chemotherapy; six achieved CR after chemother-
apy, one achieved PR (normalized tumor markers and gross resid-
ual disease) and underwent surgery revealing teratoma. One female
developedmultiple pelvic peritoneal nodules ofmature teratoma after
47months (Table 3).
The one stage IV case had liver and peritoneal metastases (AFP:
1,440). After surgery, and two BEP cycles, she had PD, so the
chemotherapy was changed, achieving PR. Teratoma was identi-
fied after delayed surgery. Thirty-four months after diagnosis, the
residual infradiaphragmatic disease spread rapidly and she died after
an attempted resection. Pathology showed teratoma with malignant
transformation (primitive neuroectodermal tumor [pNET]; Table 3).
In all IT + AFP patients, the 5-year OS and EFS rates were 92.3%
(95%CI: 78.8–100%) and 82.5% (95%CI: 63.1–100%), respectively.
Non-Dysg: Among 38 patients, 11 were stage I and were moni-
tored closely after surgery, and had no chemotherapy. Twohad surgery
according to the original surgical guidelines, seven according to the
revised version, two underwent OO. Four patients relapsed (one with-
out PWC, one without normalized AFP after surgery, two properly
staged) a median 3 months after diagnosis (Table 3). They all received
chemotherapy, and two of four patients also had surgery (one before,
one after chemotherapy), with no impact on fertility. All are alive and in
CR.
Six cases were classified as stages II due to tumor ruptures/capsule
lacerations in three, peritoneal pelvic implants were removed in one,
no PWC in two. One patient was PD after two BEP cycles, with a
growing tumor mass despite marker normalization. She underwent
surgery, teratoma with malignant transformation was diagnosed, and
chemotherapy was administered. The diagnosis was centrally revised
to growing teratoma andmanaged surgically. The teratoma grew again
twice. At the time of writing, she was disease-free after a 82-month
follow-up (Table 3). All patients achieved CR: five after three cycles of
BEP, one after chemotherapy and surgery.
The reasons for 17 patients being stage III were as follows: resid-
ual mass and/or peritoneal implants in eight, PWC positivity in three,
metastatic lymph nodes in three, and because no PWC was per-
formed after tumor rupture in three. Thirteen (76%) achieved CR after
chemotherapy. Four (24%) had PR (normalized tumor markers and
gross residual disease) and underwent surgery, revealing teratoma in
two and fibronecrotic tissue in two.
No stage III patients relapsed with malignant disease. One relapsed
twice with growing teratoma, 11 and 39months after delayed surgery
(Table 3). Among the four patients with stage IV, two were under 11
years of age andhad lungmetastases, twowere older, and onehad liver
metastases, the other had elevatedAFP andbetaHCG levels, and unre-
ported sites of metastases. All but one of these patients underwent
OO and received chemotherapy. There were two CR and two PR (with
normalized markers), one with lung and the other with ovary involve-
ment. Lung metastasectomy revealed viable malignant cells and, after
twomoreBEP cycles, the patientwas alive and disease-free 32months
after diagnosis. OO identified teratoma in the other. Overall, there
were two CR, one teratoma, and one case of viable malignant cells. All
patients are alive and in CR. The 5-year OS for all Non-Dysg patients
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TABLE 2 Clinical and pathologic characteristics of patients withMOGCT
Dysg Non-Dysg IT+AFP
N= 26 N= 38 N= 13
Age (years), n (%)
<11 5 (19) 22 (58) 6 (46)
≥11 21 (81) 16 (42) 7 (54)
AFP at diagnosis (ng/mL), n (%)
≤1,000 - 5 (13) 8 (62)
1,000–10,000 - 12 (32) 4 (31)
≥10,000 - 15 (39) 0 (0)
Unknown - 4 (11) 1 (8)
Normal value - 2 (5) 0 (0)
𝛽HCG at diagnosis [UI/l], n (%)
≤ 5,000 8 (31) 5 (13) -
5,000–50,000 1 (4) 5 (13) -
≥50,000 0 (0) 3 (8) -
Unknown 7 (27) 4 (11) -
Normal value 10 (38) 21 (55)
5-year EFS all, % (95%CI) 86.6 (73.4–100) 84.2 (73.4–96.6) 82.5 (63.1–100)
5-year EFS stage I, % (95%CI) 72.9 (50.7–100) 63.6 (40.7–99.5) 100
5-year EFS stages II–IV, % (95%CI) 100 92.6 (83.2–100) 76.2 (52.1–100)
Stage I Stage II Stage III Stage I Stage II Stage III Stage IV Stage I Stage II Stage III Stage IV
N= 13 N= 6 N= 7 N= 11 N= 6 N= 17 N= 4 N= 3 N= 1 N= 8 N= 1
Surgical staging, n (%)
Surgical staging
2004
5 (38) 2 (33) 5 (71) 2 (18) 1 (17) 2 (12) – 1 (33) 1 (100) 3 (38) –
Staging with
washing only
5 (38) 2 (33) 1 (14) 7 (64) 1 (17) 7 (41) 3 (75) 2 (64) – 3 (38) 1 (100)
OO 2 (15) 2 (33) – 2 (18) 3 (50) 5 (29) – – – 1 (13) –
Biopsy only – – 1 (14) – – 2 (12) 1 (25) – – 1 (13)a –
No surgery, no
biopsy
– – – – – 1 (6) – – – – –
Unknown 1 (18)a – – – 1 (17) – – – – – –
Reason for stage II—II–IV, n description
– 2 LN+ 3 LN+ – 3 Ruptures 3 LN+ 2 Lung
metastases
– 1 Implant
removed
5 Implants/
residual mass
1 Liver
metastasis
2 Ruptures 2 PWC+ 2No PWC 8 Implants/
residual mass
1 Liver
metastasis
2 PWC+
2 Peritubaric
tissue
2 Residual
mass
1 Implant
removed
3 PWC+ 1Unknown 1Unknown
3 Ruptures+
no PWC
CR after
chemotherapy, n
(%)
– 6 (100) 6 (86) – 5 (83) 13 (76) 2 (50) – 1 6 (75) 0 (0)
CR after
chemotherapy and
surgery, n (%)
0 (0) 0 (0) 1 (14) – 1 (17) 4 (24) 2 (50) 0 (0) 0 (0) 1 (13) 0 (0)
n Description 1 Viable
malignant
cell
1 Teratoma 2
Fibronecrotic
tissue
1 Teratoma 1 Teratoma
2 Teratoma 1 Viable
malignant cells
Events, n (%) 3 (23) 0 (0) 0 (0) 4 (36) 1 (17) 1 (6) 0 (0) 0 (0) 0 (0) 1 (13) 1 (100)
aLost to follow-up ; LN+, metastatic lymph nodes; PWC+, PWCwithmalignant cells.
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TABLE 3 Events in patients all stages
Age
(years)
Primary
tumor
histology
Stage and
markers at
diagnosis
Adherence to
surgical
staging Treatments EFS (months)
Event
histology Site Status
Treatment
event
OS
(months)
16 Dysg I
Normal values
Yes Surveillance 40 Dysg Lymph nodes CR Biopsy, BEP ×
4 cycles
102
9 Dysg I
Not done
No Surveillance 25 Dysg Pelvic mass CR Biopsy, BEP ×
4 cycles
113
10 Dysg I
betaHCG
Yes Surveillance 21 Dysg Lymph nodes,
betaHCG
CR Biopsy, BEP ×
4 cycles→ S
(fibronecrotic
tissue)
33
6 Non-Dysg I
AFP–
betaHCG
Yes Surveillance 3 Not done AFP–
betaHCG
CR BEP × 4 cycles 80
12 Non-Dysg I
Not done
Yes without
AFP
normalization
Surveillance 3 Non-Dysg Peritoneal
implants, AFP
CR Biopsy, BEP ×
4 cycles→ S
(teratoma)
28
3 Non-Dysg I
Not done
No Surveillance 3 Non-Dysg Peritoneal
implants,
AFP–
betaHCG
CR S→BEP × 6
cycles
103
9 Non-Dysg AFP Yes Surveillance 3 Not done Liver
metastases,
peritoneal,
implants, AFP
CR BEP × 2→ ICE
× 2 and
high-dose
chemotherapy
111
10 Non-Dysg II
AFP–
betaHCG
No S→BEP × 2
→ S
5 Growing
teratoma
Abdominal
masses
peritoneal
diffusion and
hepatic
nodules
CR S 82
12 Non-Dysg III
AFP–
betaHCG
Yes S→BEP × 4
→ S
12 Growing
teratoma
Abdominal
and pelvic
mass, lymph
nodes, hepatic
nodules
CR S 137
11 IT+AFP III
AFP (1,438
ng/ml)
Yes S→BEP × 4 47 Mature
teratoma
Pelvic masses CR S 65
15 IT+AFP IV AFP (1,440
ng/ml)
Yes S→BEP × 2
→ PD
3 Not done Peritoneal
diffusion
PD 2nd line CT
→ S
(teratoma)/34
months
primitive neu-
roectodermal
tumor (pNET)
34 (EX)
was 100%, and 5-year EFS rates were 84.2% (95% CI: 73.4–96.6%) for
them all, 63.6% (95% CI: 40.7–99.5%) for stage I, and 92.6% (95% CI:
83.2–100%) for stages II–IV.
3.1 Overall results
Thirty-nine of 49 (80%) patients achieved CR after chemotherapy
alone, and another 9 of 49 (total 98%) after adding delayed surgery.
Histology in the latter revealed fibronecrotic tissue in two (4%), viable
malignant cells in two (4%), and teratoma in five (10%). All but one of
these patientswas alive at the last follow-up (5-yearOS98.5%, 95%CI:
95.6–100%)and the5-yearEFSwas84.5% (95%CI: 76.5–93.5%) for all
stages, 91.1% (95% CI: 83.1–99.9%) for stages II–IV, and 72.1% (95%
CI: 56.4–92.1%) for stage I (Figs. 1 and 2). The 5-year EFS did not vary
significantly with known prognostic factors11: 5-year EFS 85.8% (95%
CI: 76.4–96.2%) for patients ≥11 years of age, 81.3% (95% CI: 66.3–
99.7%) for those<11 years of age(log-rank testP=0.564); 86.6% (95%
CI: 73.4–100%) for Dysg, and 84.2% (95% CI: 73.4–96.6%) for Non-
Dysg (log-rank test P= 0.614). Themedian follow-up was 80months.
3.2 Toxicity
Chemotherapy was well tolerated and there were no toxic deaths,
secondary leukemias, or cancers. One female had a severe skin
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F IGURE 1 Event-free survival and overall survival—stage I
F IGURE 2 Event-free survival and overall survival—all stages
reaction after a second dose of bleomycin and the drug was subse-
quently omitted. Three patients had bilateral tumors and none under-
went bilateral OO (one of them had iatrogenic amenorrhea). No lung
or acoustic nerve impairments were identified after chemotherapy or
during the follow-up. One pregnancy with offspring in good health has
been reported.
4 DISCUSSION
We describe the second Italian case series of MOGCT. Compared to
the first,3 we found a higher number of cases because of the extended
ageof enrolment andgreater awarenessof somegynecologists, though
pediatric cases areprobably still underreported; abetter survival (from
a 33-month OS of 88.2% to a 5-year OS of 98.5%; and from 33-month
EFS of 80.8% to a 5-year EFS of 84.5%), probably due to a more effec-
tive drug regimen; and a lower burden of treatment, since all Non-
Dysgpatients hadpreviously received chemotherapy, and stage IIDysg
patients had received radiotherapy.
This study confirms the excellent prognosis for Dysg patients,
although our P-value was not significant when they were compared
to Non-Dysg patients: none had distant metastases at diagnosis, and
all stage II and III cases were cured without subsequent events. We
recommend a strict follow-up with markers and ultrasound, reserving
computed tomography and/or MRI for selected cases. Given the value
of tumor markers for monitoring purpose, we prefer to use ultrasound
to contain patients’ radiological exposure during their follow-up. Even
if Dysg patients lack informative AFP (often also betaHCG) levels, they
should be followed up with ultrasound too, although Dysg relapses
later and demands a prolonged follow-up. It has already been reported
in adults that >90% of relapses in Dysg patients occur within 3 years,
and those in Non-Dysg patients appear within 2 years.12 This was true
of our series too, and it is important to bear this in mind to ensure a
proper follow-up (Table 3).
There is no consensus on the management of ovarian IT, and
their inclusion in analyses on MOGCT is debated: approaches differ
between adults and pediatric professionals, and even between pedi-
atric series.13–16 We included IT with elevated AFP because central
pathology review was not mandatory and there was a risk of missing
some foci of YST within IT17: in 2004, we chose to include IT with AFP
level cutoff “high for age,” which is why we had such a wide range.
This is another controversial issue: somenational pediatric groups (UK,
COG)16–18 adopt an AFP cutoff for treating IT, while others do not.We
acknowledge that having no cutoff can be misleading and an interna-
tional agreement is needed.
The surveillance-alone strategy for Non-Dysg histotypes has
recently beenwidely debated. Pediatric specialists and someEuropean
groups7,13,17,19–21 support this strategy in adults too. Pediatricians
worry about the long-term treatment sequelae (neuro- and nephro-
toxicity, lung fibrosis, hypertension, and etoposide-related secondary
leukemia,22) and try to avoid chemotherapy. Cisplatin is measurable
in the serum for years after exposure, and detectable in every bod-
ily organ at autopsy.23,24 The cumulative prevalence of serious or life-
threatening chronicmedical conditions by 45 years of age among pedi-
atric cancer survivors is reportedly as high as 80%, suggesting prema-
ture aging as a consequence of childhood cancer therapies.25 Some
adult specialists are more cautious, especially for YST, and prescribe
chemotherapy systematically because recurrences are rare, but poten-
tially lethal.26,27 Another argument in favor of chemotherapy is con-
cerned with the potential impact on fertility of further surgery for
patients who relapse,26 and the need for more chemotherapy.
We realize that surveillance alone exposes some females to the risk
of recurrence, but in our experience almost all of those who recur
are rescued with standard-dose chemotherapy, with/without further
surgery, with no impact on fertility. This seems a fair price to pay for
the benefit to our patients spared any chemotherapy.
There is another point to consider in patients with resid-
ual/recurrent growing masses and a teratoma component in their
original tumor: if their tumor markers remain normal, it is not a pro-
gression. The so-called chemotherapeutic retroconversion or growing
teratoma28 is not so rare: Zagamé et al. reported an incidence of
12% in their pediatric and adult series,29 and it was 5% in our series.
Growing teratoma should be managed with surgery, which is both
diagnostic and the mainstay of therapy. Subsequent surgery may
be needed to remove all localizations and late recurrences,28 so a
prolonged follow-up is warranted. Awareness of growing teratoma
is essential to avoid unnecessary chemotherapy. If surgery carries
a significant risk, follow-up may be appropriate. Lesions can remain
stable for years, but if they grow, a somatic malignant transformation
should be ruled out. There is a risk of malignant transformation in
every residual teratoma and debulking surgery is recommended, also
for histological purposes, then the most appropriate treatment can be
decided for the particular transformation underway. This applies to
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any residual disease after chemotherapy: the role of surgery is curative
and diagnostic too, revealing different categories of residual disease
(fibronecrotic tissue, teratoma, viable malignant cells).
Some issues are common to all histotypes. Whether surgical stag-
ing must be more extensive (as claimed by gynecological oncologists)
or less so (as recommended by pediatric surgeons),4–8 remains unclear,
and no randomized trials are available.19 The role of lymph node dis-
section is also debated5: gynecological oncologists consider it funda-
mental (especially in Dysg) because dissemination is more often lym-
phatic than intraperitoneal.19 But without pathological tumor mark-
ers at diagnosis, ovarian masses may be indistinguishable from ter-
atomas (for which lymphadenectomy is unnecessary). In our series,
LNS was initially recommended, then omitted if the lymph nodes
seemed normal. It is important to discuss these details to prompt pedi-
atric surgeons to examine the nodes during surgery, perform PWC,
and carefully assess the retroperitoneal lymph nodes on baseline com-
puted tomography. Given the lack of conclusive scientific data on the
most appropriate surgical staging,19 the patients’ age and long life
expectancy, and the high cure rates after relapses, as pediatric pro-
fessionals we advise against excessively aggressive front-line surgery,
and favor a minimal invasiveness. More extensive surgery should be
reserved for relapsing patients, where necessary.
Noncompliance with surgical guidelines is a known issue for
MOGCT and other neoplasms in pediatric and adult patients,8,30–34
and was seen in our sample too. It is of special concern for patients
with stage I. Themulticenter Italian trial30 reported that stage IADysg
(according to the FIGO classification) is incorrectly staged in 20% of
adult cases, but about 15%of appropriately staged patients reportedly
recur,35 so the benefit of accurate staging seemsminimal. In the review
by Palenzuela et al.,31 none of the patients staged appropriately as IA
and about 40% of those staged inappropriately recurred (though all
relapsing patients could be cured). This was true of our series too. How
to manage cases inappropriately classified as stage I is a controversial
issue and many questions remain. There are too many options and no
certainty concerning adjuvant chemotherapy (and its side effects) or
surgical restaging; upstaging after appropriate surgery; the avoidance
of any treatment until relapse (given the high cure rates afterwards),
and the experience of recurrences irrespective of type of surgery per-
formed; more intensive follow-ups for incorrectly staged cases. All the
possible options have their pros and cons, and many issues need to be
balanced and taken into account. Pediatric guidelines focus onminimal
surgical invasiveness. Caseswithout PWC, proper surgical exploration,
or tumor marker assays should reasonably be classified as stage II, and
receive chemotherapy.
Ourpatients in stages II–IVwere too few to identify anydifferences,
but the proposed prognostic indicators11,36 suggest that females with
stage IV MOGCT >11 years of age have a worse disease-free survival
(<70%). With only five metastatic cases, it is impossible to draw any
conclusions, but theonly patientwith refractorymalignant diseasewas
in stage IV and>11 years of age.
The Children’s Oncology Group7 had already compared the use of
a compressed BEP regimen with standard BEP,26,37–39 and the Brazil-
ian group omitted bleomycin in intermediate-risk patients.14 Wedeliv-
ered BEP in 4 days, with a single dose of bleomycin, and reduced
the etoposide too. These dose reductions did not seem to influence
survival, though randomized trials in adult male series showed worse
results after reducing doses of bleomycin and etoposide40 and alter-
native combinations did not achieve better results in terms of sur-
vival or toxicity.23,39 Standard BEP remains the gold standard for adult
GCT.38,39 Our BEP regimen was changed to minimize the risk of late
sequelae and survival rates were excellent after low cumulative doses
of etoposide and bleomycin. None of our patients have had secondary
leukemia or severe late effects to date, though it is impossible to draw
conclusions.
In conclusion, femaleswithMOGCTgenerally haveanexcellentout-
come, with a low burden of surgery and chemotherapy, and (hopefully)
of late sequelae. Robust data and randomized trials are lacking, how-
ever, on surgical staging, surveillance for Non-Dysg with stage I, IT
management, the “right”AFPcutoff, the typeofBEP for youngpatients.
As pediatric oncologists, we support the role of surveillance after min-
imal but accurate surgical staging, providing the case is handled by
experts at specialized pediatric centers, as already reported by gyne-
cological centers.31,41
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